CD19 and neoplasm: Effective debulking chemotherapy should therefore be administered to patients with R/R DLBCL with high tumor bulk prior to anti-CD19-CAR-T therapy to decrease tumor burden and thereby improve the short- and long-term efficacy of anti-CD19-CAR-T therapy.